Blueprint Medicines has completed a $25 million round of Series B financing to pursue its patient-focused vision of developing tailored, genomic-specific cancer treatments.
Close to a decade after a pair of investigators from Baylor College of Medicine launched Bellicum Pharmaceuticals in Houston, the biotech has added $14.7 million to its Series B round, which will help expand an ongoing Phase I/II study of its lead therapy for graft vs. host disease.
The venture capital wing of Google has once again backed DNAnexus, joining with other existing investors and newcomer Claremont Creek Ventures to commit $15 million.
Google Ventures has joined a group of investors seeding DNAnexus' cloud-computing services for biomedical researchers with a $15 million C round.
Biotech management company NeXeption has locked in $21.5 million in a Series A round of financing to form Alexar Therapeutics, a company with a focus on treating skin disorders called inflammatory cutaneous disorders.
North Carolina's Argos Therapeutics believes it can succeed where Dendreon has faltered, pitching a $60 million IPO that would help the biotech get its personalized cancer therapy through Phase III.
The British biotech has rounded up $28 million (£17.5 million) in first-round venture cash from a group of marquee investors willing to bet big that Crescendo's mouse platform can deliver the best in cutting-edge antibody fragment therapeutics.
A little more than a year after launching with a portfolio of 6 early-stage assets from Amgen, Atara Biotherapeutics has rounded up $38.5 million in the first close of its Series B round, fueling its drive into Phase II with a lead asset while teeing up another program for its entry into the clinic.
Amgen, Celgene and Eli Lilly joined forces with some prominent venture players to back a $26 million round for Sutro Biopharma, a San Francisco-based biotech which has been garnering some careful scrutiny for its work on antibodies.
Swiss biotech startup Covagen landed a new round of venture backing today that could reach up to $63 million, enough to cover a Phase II program for its lead anti-inflammatory drug along with some follow-up work in oncology.